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the biological activity of the Ras proteins, the key molecular path-
ways downstream of K-Ras involved in promoting lung tumorigenesis 
need to be identiﬁed in order to provide better targets for lung cancer 
therapy. We hypothesize that a crucial target of oncogenic K-Ras in the 
lung is nuclear factor kappa B (NFκB). NFκB is a dimeric transcription 
factor that promotes proliferation, mediates resistance to apoptosis, and 
is abnormally activated in a large variety of human malignancies. 
Methods: In order to analyze the role of NFκB downstream of K-Ras 
in the airway epithelium, a tetracycline-inducible system was used 
to stably and inducibly express either the wild type form of K-Ras 
(K-RasWT) or the oncogenic form (K-RasV12) in the lung adenocarci-
noma H1703 cell line. We also analyzed primary human bronchial cells 
that were either immortalized (AALEB) or immortalized and trans-
formed with K-RasV12 (AALEB-K-Ras). NFκB activity in these cells 
was analyzed by western blotting, eletrophoretic mobility shift assays, 
luciferase assays and expression of NFκB target genes by real-time 
PCR. 
Results: Expression of K-Ras-WT or K-RasV12 in H1703 cells after 
tetracycline induction was accompanied by both increased expression 
of NFκB target genes, and increased NFκB DNA binding activity. 
DNA binding was mediated primarily by p50 and p65 NFκB subunits. 
Although NFκB luciferase reporter activity was detectable prior to K-
Ras expression, expression of K-RasV12, but not K-Ras-WT, enhanced 
NFκB activity. Interestingly, K-RasV12 does not activate NFκB by the 
canonical NFκB activation pathway; in both H1703 and AALEB cells 
expressing K-RasV12, there was no increase in IkappaBalpha (IκBα) 
phosphorylation/degradation. Nonetheless, activation seems to be 
dependent on IkappaB kinase (IKK) activity for the following reasons: 
(1) When compared to AALEB cells, AALEB K-Ras cells displayed 
increased IKK phosphorylation levels; and (2) speciﬁc inhibition of 
IKKβ activity in H1703 cells by the novel pyridine derivative com-
pound 65-1942 (obtained under MTA agreement with Bayer) sup-
pressed NFκB activity. Finally, as no increase in p65 phosphorylation 
at S536 was observed in either cell type expressing K-RasV12, the 
mechanism of NFκB activation does not involve direct phosphorylation 
of p65 at S536 by IKK. 
Conclusions: We have determined a causal link between K-RasV12 
expression and NFκB activation in lung epithelial cells in vitro. NFκB 
in these cells is not activated either by the canonical pathway of IκBα 
phosphorylation/degradation or by p65 phosphorylation at S536. Al-
though the speciﬁc mechanism of activation is being investigated both 
in H1703 and in primary AALEB cells, we have shown that it depends 
on IKK. IKKβ inhibitors, therefore, represent a potentially promising 
new therapeutic direction in lung cancer. Studies are underway to con-
ﬁrm their efﬁcacy in a pre-clinical lung cancer mouse model.
P2-116 BSTB: Tumor and Cell Biology Posters, Tue, Sept 4 
Gefitinib enhanced antitubulin cytotoxic effects in high P-
glycoprotein and wild epidermal growth factor receptor expressing 
non-small cell lung cancer cells by inhibiting ATP binding cassette 
transporters
Chang, Kuo-Ting Hsiao, Shih-Yin Chiu, Fan-Hsiang Tsai, Chun-Ming 
Section of Thoracic Oncology, Chest Department, Taipei Veterans Gen. 
Hospital, Taipei, Taiwan
Background: Geﬁtinib, a selective tyrosine kinase inhibitor (TKI) of 
epidermal growth factor receptor (EGFR), may inhibit functions of 
ATP-binding cassette (ABC) transporters by competing against the ATP 
binding sites. The aim of this study is to investigate the combination 
effects of geﬁtinib plus four commomly used chemotherapeutic agents 
for the treatment of non-small cell lung cancer (NSCLC) in a geﬁtinib-
insensitive lung cancer cell line and its adriamycin-induced multi-drug 
resistant subclones. 
Methods: NCI-H23 was a lung adenocarcinoma cell line with wide 
type EGFR gene expression. Its high P-glycoprotein (Pgp) expression 
subclones H23 adr 0.1 and H23 adr 0.3 were developed by stepwise 
exposure to escalating concentrations of adriamycin. The expression 
levels of (Pgp), breast cancer resistant protein (BCRP), and mutidrug 
resistant protein-1 (MRP-1) were checked by RT-QPCR and immunob-
lot. The combination effects of geﬁtinib plus single chemotherapeutic 
agents including paclitaxel (Pac), docetaxel (Doc), vinorelbine (NVB) 
and gemcitabine (Gem) were evaluated by using the tetrazolium dye 
colormetric assay with application of the classical isobole methods in 
these cell lines. To evaluate the inhibition of ABC transporters-medi-
ated drugs efﬂux, Rhodamine 6G was used as the ﬂuorescence probe 
for evaluating the inhibitory effects of geﬁtinib (0-10 μM) on the ABC 
transporters. 
Results: We found that H23 Pgp subclones showed increased resis-
tance to three antitubulins, Pac, Doc and NVB, but not to Gem and ge-
ﬁtinib. Geﬁtinib could partially reverse Pgp related Pac, Doc and NVB 
resistance in a dose-dependent fashion, showing marked synergistic ef-
fects, while geﬁtinib showed an additive combination effect with Gem. 
There was no statistical difference in the values of combination index 
between geﬁtinib plus each antitubulins. Rhodamine 6G-efﬂux assay in 
the tested cell lines revealed that ﬂuorescence-efﬂux was inhibited with 
ﬂuorescence accumulation by geﬁtinib in a dose-dependent fashion. 
Conclusions: Our results showed that geﬁtinib could enhance cytotox-
icities of anti-tubulines in Pgp expressing NSCLC cells which showed 
wild type EGFR. Our results provide a rationale to test these combina-
tions as salvage treatment in NSCLC patients who failed prior antitubu-
lin treatment and also in patients whose tumors express high Pgp.
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Animal studies demonstrated that females are more susceptible than 
males to benzo[a]pyrene (BaP)-induced toxicities, including lung car-
cinogenesis. Elevation of cyclooxygenase-2 (COX-2) ex-pression has 
been shown to increase the risk of cancer development. BaP induces 
COX-2 expression, and an interaction between BaP and estrogen in 
relation to COX-2 expression is suspected. In the present study, 10 
mMBaP alone only slightly increased COX-2 mRNA expression and 
10 nM 17-beta estradiol (E2) alone slightly increased prostaglandin 
E2 (PGE2) secretion in human bronchial epithelial cells. However, 
co-treatment with BaP and E2 potentiated COX-2 mRNA expression 
and signiﬁcantly elevated PGE2 secretion. Utilizing speciﬁc inhibitors 
and reporter assays, we further investigated the potentiation mecha-
nisms of E2 on BaP-induced COX-2 expression. First, E2 activated 
estrogen receptor to increase PGE2 secretion, which directly increased 
